Advertisement

Endocrine

, Volume 48, Issue 2, pp 428–433 | Cite as

Metformin in women with PCOS, CONS

  • Marie L. Misso
  • Helena J. Teede
Pros and Cons in Endocrine Practice

Abstract

Metformin has a potential role for insulin resistance in polycystic ovary syndrome(PCOS) and has demonstrated efficacy in diabetes. There are a large number of studies and evidence syntheses comparing metformin with control, lifestyle interventions, the oral contraceptive pill, and clomiphene citrate; however, there is still uncertainty about the effectiveness of metformin in women with PCOS. Here we present a systematic overview of the evidence for the use of metformin in women with PCOS. The evidence suggests that metformin continues to have an unclear roll in PCOS until further well designed; methodologically rigorous effectiveness studies with large sample sizes are conducted, and these should include women across the body mass index (BMI) range.

Keywords

Polycystic ovary syndrome Metformin Infertility Menstrual cycle regulation Hirsutism Diabetes and cardiovascular disease risk 

References

  1. 1.
    W.A. March, V.M. Moore, K.J. Willson, D.I. Phillips, R.J. Norman, M.J. Davies, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25(2), 544–551 (2010). doi: 10.1093/humrep/dep399 CrossRefPubMedGoogle Scholar
  2. 2.
    J.A. Boyle, J. Cunningham, K. O’Dea, T. Dunbar, R.J. Norman, Prevalence of polycystic ovary syndrome in a sample of indigenous women in Darwin, Australia. Med. J. Aust. 196(1), 62–66 (2012)CrossRefPubMedGoogle Scholar
  3. 3.
    S.R. Davis, S. Knight, V. White, C. Claridge, B.J. Davis, R. Bell, Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecol. Endocrinol. 16(6), 443–446 (2002)CrossRefPubMedGoogle Scholar
  4. 4.
    M. Hickey, D.A. Doherty, H. Atkinson, D.M. Sloboda, S. Franks, R.J. Norman, R. Hart, Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum. Reprod. 26(6), 1469–1477 (2011). doi: 10.1093/humrep/der102 CrossRefPubMedGoogle Scholar
  5. 5.
    NIH Evidence based workshop on Polycystic Ovary Syndrome. http://prevention.nih.gov/workshops/2012/pcos/resources.aspx. (2012)
  6. 6.
    B.O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, H. Yarali, Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. (Oxford, England) 27(10), 3067–3073 (2012)CrossRefGoogle Scholar
  7. 7.
    R.J.R.J. Norman, D.D. Dewailly, R.S.R.S. Legro, T.E.T.E. Hickey, Polycystic ovary syndrome. Lancet 370(9588), 685–697 (2007)CrossRefPubMedGoogle Scholar
  8. 8.
    H.J. Teede, A.E. Joham, E. Paul, L.J. Moran, D. Loxton, D. Jolley, C. Lombard, Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (2013). doi: 10.1002/oby.20213 Google Scholar
  9. 9.
    H.J. Teede, M.L. Misso, A.A. Deeks, L.J. Moran, B.G. Stuckey, J.L. Wong, R.J. Norman, M.F. Costello, Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med. J. Aust. 195(6), S65–S112 (2011)CrossRefPubMedGoogle Scholar
  10. 10.
    N.K. Stepto, S. Cassar, A.E. Joham, S.K. Hutchison, C.L. Harrison, R.F. Goldstein, H.J. Teede, Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum. Reprod. 28(3), 777–784 (2013)CrossRefPubMedGoogle Scholar
  11. 11.
    E. Diamanti-Kandarakis, A. Dunaif, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr. Rev. 33(6), 981–1030 (2012). doi: 10.1210/er.2011-1034 CrossRefPubMedGoogle Scholar
  12. 12.
    L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16(4), 347–363 (2010)CrossRefPubMedGoogle Scholar
  13. 13.
    R.A. Wild, E. Carmina, E. Diamanti-Kandarakis, A. Dokras, H.F. Escobar-Morreale, W. Futterweit, R. Lobo, R.J. Norman, E. Talbott, D.A. Dumesic, Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95(5), 2038–2049 (2010). doi: 10.1210/jc.2009-2724 CrossRefPubMedGoogle Scholar
  14. 14.
    L.J. Moran, A.A. Deeks, M.E. Gibson-Helm, H.J. Teede, Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. 27(7), 2082–2088 (2012). doi: 10.1093/humrep/des114 CrossRefPubMedGoogle Scholar
  15. 15.
    A.A. Deeks, M.E. Gibson-Helm, E. Paul, H.J. Teede, Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Hum. Reprod. 26(6), 1399–1407 (2011)CrossRefPubMedGoogle Scholar
  16. 16.
    L.C. Giudice, Endometrium in PCOS: implantation and predisposition to endocrine CA. Best. Pract. Res. Clin. Endocrinol. Metab. 20(2), 235–244 (2006)CrossRefPubMedGoogle Scholar
  17. 17.
    B.C.J.M. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo, E. Carmina, J. Chang, B.O. Yildiz, J.S.E. Laven, J. Boivin, F. Petraglia, C.N. Wijeyeratne, R.J. Norman, A. Dunaif, S. Franks, R.A. Wild, D. Dumesic, K. Barnhart, Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97(1), 28–38 (2012)CrossRefPubMedGoogle Scholar
  18. 18.
    H.J. Teede, A.E. Joham, E. Paul, L.J. Moran, D. Loxton, D. Jolley, C. Lombard, Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity 21(8), 1526–1532 (2013)CrossRefPubMedGoogle Scholar
  19. 19.
    R. Pasquali, Metformin in women with PCOS. Pros. Endocrine (2014). doi: 10.1007/s12020-014-0311-1 Google Scholar
  20. 20.
    PCOS Australian Alliance: Evidence based guidelines for assessment and management of polycystic ovary syndrome. In: Jean Hailes Foundation for Women’s Health on behalf of the PCOS Australian Alliance Melbourne (2011)Google Scholar
  21. 21.
    R.S. Legro, S.A. Arslanian, D.A. Ehrmann, K.M. Hoeger, M.H. Murad, R. Pasquali, C.K. Welt, Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 98(12), 4565–4592 (2013). doi: 10.1210/jc.2013-2350 CrossRefPubMedGoogle Scholar
  22. 22.
    T. Bridger, S. MacDonald, F. Baltzer, C. Rodd, Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch. Pediatr. Adolesc. Med. 160(3), 241–246 (2006)CrossRefPubMedGoogle Scholar
  23. 23.
    L. Morin-Papunen, A.S. Rantala, L. Unkila-Kallio, A. Tiitinen, M. Hippelainen, A. Perheentupa, H. Tinkanen, R. Bloigu, K. Puukka, A. Ruokonen, J.S. Tapanainen, Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J. Clin. Endocrinol. Metab. 97(5), 1492–1500 (2012). doi: 10.1210/jc.2011-3061 CrossRefPubMedGoogle Scholar
  24. 24.
    D. Romualdi, M. Giuliani, F. Cristello, A.M. Fulghesu, L. Selvaggi, A. Lanzone, M. Guido, Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil. Steril. 93(7), 2303–2310 (2010). doi: 10.1016/j.fertnstert.2009.01.114 CrossRefPubMedGoogle Scholar
  25. 25.
    M. Costello, B. Shrestha, J. Eden, P. Sjoblom, N. Johnson, Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst. Rev. (1), CD005552 (2007)Google Scholar
  26. 26.
    Z. Jing, X. Liang-Zhi, W. Tai-Xiang, T. Ying, J. Yu-Jian, The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol. Endocrinol. 24(10), 590–600 (2008). doi: 10.1080/09513590802288242 CrossRefPubMedGoogle Scholar
  27. 27.
    C. Meyer, B. McGrath, H. Teede, Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30, 471–478 (2007)CrossRefPubMedGoogle Scholar
  28. 28.
    D.D.G. Curi, A.M. Fonseca, J.A.M. Marcondes, J.A.M. Almeida, V.R. Bagnoli, J.M. Soares Jr, E.C. Baracat, Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol. Endocrinol 28(3), 182–185 (2012). doi: 10.3109/09513590.2011.583957 CrossRefPubMedGoogle Scholar
  29. 29.
    K.A. Martin, R.J. Chang, D.A. Ehrmann, L. Ibanez, R.A. Lobo, R.L. Rosenfield, J. Shapiro, V.M. Montori, B.A. Swiglo, Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(4), 1105–1120 (2008). doi: 10.1210/jc.2007-2437 CrossRefPubMedGoogle Scholar
  30. 30.
    T. Tang, J.M. Lord, R.J. Norman, E. Yasmin, A.H. Balen, Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 5, CD003053 (2012). doi: 10.1002/14651858.CD003053.pub5
  31. 31.
    M. Luque-Ramirez, F. Alvarez-Blasco, J.I. Botella-Carretero, E. Martinez-Bermejo, M.A. Lasuncion, H.F. Escobar-Morreale, Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92(7), 2453–2461 (2007)CrossRefPubMedGoogle Scholar
  32. 32.
    K.M. Hoeger, L. Kochman, N. Wixom, K. Craig, R.K. Miller, D.S. Guzick, A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil. Steril. 82(2), 421–429 (2004)CrossRefPubMedGoogle Scholar
  33. 33.
    H.S. Qublan, E.K. Yannakoula, M.A. Al-Qudah, F.I. El-Uri, Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med. J. 28(11), 1694–1699 (2007)PubMedGoogle Scholar
  34. 34.
    K. Hoeger, K. Davidson, L. Kochman, T. Cherry, L. Kopin, D.S. Guzick, The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J. Clin. Endocrinol. Metab. 93(11), 4299–4306 (2008). doi: 10.1210/jc.2008-0461 CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    P. Popova, E. Ryasantseva, I. Zazerskaya, L. Ivanova, E. Grineva, The role of weight loss and metformin in the improvement of menstrual function in overweight and obese women with polycystic ovary syndrome. Diabetes, Obes. Metab. 12, 87 (2010). doi: 10.1111/j.1463-1326.2010.01284.x Google Scholar
  36. 36.
    R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, D. Colitta, S. Fiorini, G.E. Cognigni, M. Filicori, A.M. Morselli-Labate, Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85(8), 2767–2774 (2000)CrossRefPubMedGoogle Scholar
  37. 37.
    X. Sun, D. Zhang, W. Zhang, Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch. Gynecol. Obstet. 288(2), 423–430 (2013). doi: 10.1007/s00404-013-2756-5 CrossRefPubMedGoogle Scholar
  38. 38.
    T.I. Siebert, M.I. Viola, D.W. Steyn, T.F. Kruger, Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecol. Obstet. Invest. 73(4), 304–313 (2012). doi: 10.1159/000335253 CrossRefPubMedGoogle Scholar
  39. 39.
    J. Xiao, S. Chen, C. Zhang, S. Chang, The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. Gynecol. Endocrinol. 28(12), 956–960 (2012). doi: 10.3109/09513590.2012.705368 CrossRefPubMedGoogle Scholar
  40. 40.
    T. Moresco, V. Genro, C. Schmitz, C. Souza, J. Cunha-Filho, Metformin alone or combined with clomiphene citrate in women with polycystic ovary syndrome and infertility: systematic review. Fertil. Steril. 96, S129 (2011). doi: 10.1016/j.fertnstert.2011.07.504 CrossRefGoogle Scholar
  41. 41.
    S. Kar, Clomiphene citrate, metformin or the combination of both, as first line ovulation induction drug in polycystic ovarian syndrome: a randomised controlled trial. Fertil. Steril 1, S359–S360 (2013). doi: 10.1016/j.fertnstert.2013.07.849 Google Scholar
  42. 42.
    N. Johnson, Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome–a meta-analysis of randomised trials. Aust. N. Z. J. Obstet. Gynaecol. 51(2), 125–129 (2011). doi: 10.1111/j.1479-828X.2010.01274.x CrossRefPubMedGoogle Scholar
  43. 43.
    S. Palomba, A. Falbo, G.B. La Sala, Clomiphene citrate, metformin or both for ovulation induction in therapy naive women with polycystic ovary syndrome (PCOS)? A descriptive review. Curr. Drug Ther. 8(1), 30–37 (2013). doi: 10.2174/1574885511308010004 CrossRefGoogle Scholar
  44. 44.
    R.C. Machado, N.A. Machado, S. Geber, Evaluation of the use of metformin in ovulation result of patients with the polycystic ovary syndrome resistant to isolated use of clomiphene citrate. Jornal Brasileiro de Reproducao Assistida 16(1), 27–31 (2012)Google Scholar
  45. 45.
    M.L. Misso, M.F. Costello, M. Garrubba, J. Wong, R. Hart, L. Rombauts, A.M. Melder, R.J. Norman, H.J. Teede, Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 19(1), 2–11 (2013). doi: 10.1093/humupd/dms036 CrossRefPubMedGoogle Scholar
  46. 46.
    M.L. Misso, H.J. Teede, R. Hart, J. Wong, L. Rombauts, A.M. Melder, R.J. Norman, M.F. Costello, Status of clomiphene citrate and metformin for infertility in PCOS. Trends. Endocrinol. Metab. 23(10), 533–543 (2012). doi: 10.1016/j.tem.2012.07.001 CrossRefPubMedGoogle Scholar
  47. 47.
    M.S. Alebic, T. Bulum, N. Stojanovic, L. Duvnjak, Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine (2014). doi: 10.1007/s12020-014-0182-5 PubMedGoogle Scholar
  48. 48.
    R.E. Ratner, C.A. Christophi, B.E. Metzger, D. Dabelea, P.H. Bennett, X. Pi-Sunyer, S. Fowler, S.E. Kahn, Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J. Clin. Endocrinol. Metab. 93(12), 4774–4779 (2008). doi: 10.1210/jc.2008-0772 CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    F. Esfahanian, M.M. Zamani, R. Heshmat, Moini nia, F.: Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. J Obstet Gynaecol Res 39(4), 806–813 (2013). doi: 10.1111/j.1447-0756.2012.02051.x CrossRefPubMedGoogle Scholar
  50. 50.
    W. Knowler, E. Barrett-Connor, S. Fowler, R. Hamman, J. Lachin, E. Walker, D. Nathan, Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346(6), 393–403 (2002)CrossRefPubMedGoogle Scholar
  51. 51.
    J.L. Rosenzweig, E. Ferrannini, S.M. Grundy, S.M. Haffner, R.J. Heine, E.S. Horton, R. Kawamori, Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93(10), 3671–3689 (2008). doi: 10.1210/jc.2008-0222 CrossRefPubMedGoogle Scholar
  52. 52.
    J.P. Domecq, G. Prutsky, R.J. Mullan, V. Sundaresh, A.T. Wang, P.J. Erwin, C. Welt, D. Ehrmann, V.M. Montori, M.H. Murad, Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 98(12), 4646–4654 (2013). doi: 10.1210/jc.2013-2374 CrossRefPubMedGoogle Scholar
  53. 53.
    H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41 (2010). doi: 10.1186/1741-7015-8-41 CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Monash Centre for Health Research and Implementation, School Public Health and Preventative MedicineMonash UniversityClaytonAustralia

Personalised recommendations